◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Biocon Limited (BIOCON)
来自官方财务报表的收入、利润与现金流历史。
Healthcare · 华尔街（美国） · 最近更新： 2026-09-20
Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments.
关键数据
- 市值: ₹627 billion
- 收入（截至 2026-03-31 财年）: ₹167.8B
- 净利润: ₹3.9B
- 毛利率: 66.1%
- 净利率: 2.3%
查看交互式图表与完整报表 →
年度利润表
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|
| 总收入 | ₹167.8B | ₹150.5B | ₹142.0B | ₹109.3B |
| 毛利 | ₹110.9B | ₹98.5B | ₹92.9B | ₹72.7B |
| 营业利润（EBIT） | ₹17.2B | ₹16.3B | ₹14.3B | ₹16.3B |
| 净利 | ₹3.9B | ₹10.1B | ₹10.2B | ₹4.6B |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 BIOCON 交互式查看器。 /companies/us/BIOCON
类似公司
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.